Relationship between adiponectin, obesity and insulin resistance

Revista da Associacao Medica Brasileira

Volumn 61, Issue 1, 2015, Pages 72-80

  Balsan, Guilherme Ardenghi ^a   Da Costa Vieira, José Luiz ^b   De Oliveira, Aline Marcadenti ^b   Portal, Vera Lúcia ^c  

^a DEPARTMENT OF FOOD ENGINEERING   (Brazil)

^b INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

^c FUC RS   (Brazil)

Author keywords

Adiponectin; Insulin resistance; Obesity

Indexed keywords

ADIPONECTIN; FATTY ACID; INSULIN; ADIPONECTIN RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; BLOOD VESSEL WALL; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART MUSCLE; HUMAN; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; MEDLINE; META ANALYSIS; OBESITY; PROGNOSIS; PROTEIN SECRETION; PROTEIN STRUCTURE; QUALITATIVE RESEARCH; REVIEW; SYSTEMATIC REVIEW; ADIPOSE TISSUE; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; COMPLICATION; FEMALE; LIFESTYLE; MALE; METABOLISM; PHYSIOLOGY; RISK FACTOR;

ADIPONECTIN; ADIPOSE TISSUE; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INSULIN RESISTANCE; LIFE STYLE; MALE; OBESITY; RECEPTORS, ADIPONECTIN; RISK FACTORS;

EID: 84939428041     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/1806-9282.61.01.072     Document Type: Review

References (43)

1. Costa MC, Brito LL, Barbosa PJB, Ines L. Adiponectina e baixo risco cardiometabolico em obesas. Arq Bras Endocrinol Metab. 2011;2(004-2730):55.
2. Pelajo CF, Lopez-Benitez JM, Miller LC. Obesity and disease activity in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2012;10(1):3.
3. Olsovsky J. Obesity and diabetes. Vnitr Lek. 2003;49(12):956-9.
4. Kuo SM, Halpern MM. Lack of association between body mass index and plasma adiponectin levels in healthy adults. Int J Obes (Lond). 2011; 35(12):1487-94.
5. Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol. 2007;49(5):531-8.
6. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev. 2009;10(3):269-79.
7. Filho RFF, Mariosa LS, Ferreira SRG, Zanella MT. Gordura visceral e sindrome metabolica: mais que uma simples associacao. Arq Bras Endocrinol Metab. 2006;50(2)(0004-2730):230-38.
8. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab. 2007;92(2):571-6.
9. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012;55(9):2319-26.
10. Peterlin BL, Alexander G, Tabby D, Reichenberger E. Oligomerization statedependent elevations of adiponectin in chronic daily headache. Neurology. 2008;70(20):1905-11.
11. Vaiopoulos AG, Marinou K, Christodoulides C, Koutsilieris M. The role of adiponectin in human vascular physiology. Int J Cardiol. 2012;155(2):188-93.
12. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2003;285(3):E527-33.
13. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13(3):332-9.
14. Awazawa M, Ueki K, Inabe K, Yamauchi T, Kubota N, Kaneko K, et al. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab. 2011;13(4):401-12.
15. Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res. 2005;46(7):1369-79.
16. Lara-Castro C, Fu Y, Chung BH, Garvey WT. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 2007;18(3):263-70.
17. Sell H, Dietze-Schroeder D, Eckardt K, Eckel J. Cytokine secretion by human adipocytes is differentially regulated by adiponectin, AICAR, and troglitazone. Biochem Biophys Res Commun. 2006;343(3):700-6.
18. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002;51(6):1884-8.
19. Bacha F, Saad R, Gungor N, Arslanian SA. Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care. 2004;27(2):547-52.
20. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obesity Res. 2003;11(11):1278-89.
21. Carvalho MHC, Colaco AL, Fortes ZB. Citocinas, Disfuncao Endotelial e Resistencia a Insulina. Arq Bras Endocrinol Metab. 2006;50(2)(0004-2730):45.
22. ORourke RW, Metcalf MD, White AE, Madala A, Winters BR, Maizlin, II, et al. Depot-specific differences in inflammatory mediators and a role for NK cells and IFN-gamma in inflammation in human adipose tissue. Int J Obes (Lond). 2009;33(9):978-90.
23. Gerhardt CC, Romero IA, Cancello R, Camoin L, Strosberg AD. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol. 2001;175(1-2):81-92.
24. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012;18(3):363-74.
25. Fasshauer M, Paschke R, Stumvoll M. Adiponectin, obesity, and cardiovascular disease. Biochimie. 2004;86(11):779-84.
26. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 2009;78(6):539-52.
27. Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res. 2007;74(1):11-8.
28. Farag YM, Gaballa MR. Diabesity: an overview of a rising epidemic. Nephrol Dial Transplant. 2011;26(1):28-35.
29. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2) and AMPK/SIRT1. Nature. 2010;464(7293):1313-9.
30. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int. 2009;76(2):145-8.
31. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J. 2006;27(19):2300-9.
32. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, et al. Receptormediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011;17(1):55-63.
33. Chen MB, McAinch AJ, Macaulay SL, Castelli LA, OBrien P E, Dixon JB, et al. Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J Clin Endocrinol Metab. 2005;90(6):3665-72.
34. Debard C, Laville M, Berbe V, Loizon E, Guillet C, Morio-Liondore B, et al. Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of Type 2 diabetic patients. Diabetologia. 2004;47(5):917-25.
35. Li W, Tonelli J, Kishore P, Owen R, Goodman E, Scherer PE, et al. Insulinsensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle. Am J Physiol Endocrinol Metab. 2007;292(5):E1301-7.
36. Takagi H, Umemoto T. Telmisartan increases adiponectin levels: a metaanalysis and meta-regression of randomized head-to-head trials. Int J Cardiol. 2012;155(3):448-51.
37. Viveros MP, de Fonseca FR, Bermudez-Silva FJ, McPartland JM. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. Endocr Metab Immune Disord Drug Targets. 2008;8(3):220-30.
38. Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. Diabetes Obes Metab. 2007;9(3):282-9.
39. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113(15):1888-904.
40. Tentolouris C, Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Trikas A, et al. Endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy. Int J Cardiol. 2004;94(2-3):301-5.
41. Nakamura T, Funayama H, Kubo N, Yasu T, Kawakami M, Saito M, et al. Association of hyperadiponectinemia with severity of ventricular dysfunction in congestive heart failure. Circ J. 2006;70(12):1557-62.
42. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart. 2006;92(10):1420-4.
43. McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG, et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J. 2007;28(7):829-35.